These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 38989419)
41. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? Celsa C; Cabibbo G; Enea M; Battaglia S; Rizzo GEM; Busacca A; Giuffrida P; Stornello C; Brancatelli G; Cannella R; Gruttadauria S; Cammà C Liver Int; 2021 May; 41(5):1105-1116. PubMed ID: 33587814 [TBL] [Abstract][Full Text] [Related]
42. Objective Tumor Response of Hepatocellular Carcinoma Obtained by Transarterial Radioembolization with Iodine-131-Lipiodol Versus Transarterial Chemoembolization for Patients with and without Portal Venous Thrombosis: A Controlled Interventional Trial. Oliveira Ribeiro MC; Moda KA; Alvarez M; Koga KH; Moriguchi SM; Carvalho FC; Pinheiro RSN; Qi X; Romeiro FG Acad Radiol; 2024 May; 31(5):1839-1848. PubMed ID: 38016824 [TBL] [Abstract][Full Text] [Related]
43. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study. Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874 [TBL] [Abstract][Full Text] [Related]
44. Comparison of volume perfusion computed tomography and contrast-enhanced ultrasound for assessment of therapeutic effect of transarterial chemoembolization in patients with hepatocellular carcinoma: a preliminary report. Kaufmann S; Schulze M; Spira D; Horger M Acta Radiol; 2016 Jan; 57(1):8-12. PubMed ID: 25585848 [TBL] [Abstract][Full Text] [Related]
45. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464 [TBL] [Abstract][Full Text] [Related]
46. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study. Shi Q; Chen D; Zhou C; Liu J; Huang S; Yang C; Xiong B Cancer Manag Res; 2020; 12():5461-5468. PubMed ID: 32753963 [TBL] [Abstract][Full Text] [Related]
47. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188 [TBL] [Abstract][Full Text] [Related]
48. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680 [No Abstract] [Full Text] [Related]
49. [Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences]. Herber S; Pitton M; Mönch C; Schneider J; Manzl N; Kummer I; Kanzler S; Schuchmann M; Junginger T; Düber C; Otto G Zentralbl Chir; 2007 Aug; 132(4):306-15. PubMed ID: 17724633 [TBL] [Abstract][Full Text] [Related]
50. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. de Baere T; Arai Y; Lencioni R; Geschwind JF; Rilling W; Salem R; Matsui O; Soulen MC Cardiovasc Intervent Radiol; 2016 Mar; 39(3):334-43. PubMed ID: 26390875 [TBL] [Abstract][Full Text] [Related]
51. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization. Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739 [TBL] [Abstract][Full Text] [Related]
52. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175 [TBL] [Abstract][Full Text] [Related]
53. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. Lee HS; Kim KM; Yoon JH; Lee TR; Suh KS; Lee KU; Chung JW; Park JH; Kim CY J Clin Oncol; 2002 Nov; 20(22):4459-65. PubMed ID: 12431969 [TBL] [Abstract][Full Text] [Related]
54. Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma. Shi ZX; Li CF; Zhao LF; Sun ZQ; Cui LM; Xin YJ; Wang DQ; Kang TR; Jiang HJ Hepatobiliary Pancreat Dis Int; 2024 Aug; 23(4):361-369. PubMed ID: 37429785 [TBL] [Abstract][Full Text] [Related]
55. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065 [TBL] [Abstract][Full Text] [Related]
56. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Yodono H; Matsuo K; Shinohara A Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850 [TBL] [Abstract][Full Text] [Related]
57. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study. Yan L; Ren Y; Qian K; Kan X; Zhang H; Chen L; Liang B; Zheng C BMC Gastroenterol; 2021 Apr; 21(1):182. PubMed ID: 33879085 [TBL] [Abstract][Full Text] [Related]
58. The course and prognostic value of tumor stiffness detected by ultrasound elastography for transarterial chemoembolization of hepatocellular carcinoma. Hou S; Hua S; Cui K; Liu F; Ding K; Yuan J Quant Imaging Med Surg; 2023 Jun; 13(6):3962-3972. PubMed ID: 37284088 [TBL] [Abstract][Full Text] [Related]
59. Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco-regional control? Tamai T; Kumagai K; Sakae H; Onishi H; Tabu K; Tabu E; Muromachi K; Saishoji A; Oda K; Mawatari S; Moriuchi A; Sakurai K; Ido A Mol Clin Oncol; 2017 Dec; 7(6):1135-1141. PubMed ID: 29285389 [TBL] [Abstract][Full Text] [Related]
60. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]